Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BuEAM Conditioning for ASCT in DLBCL
NCT01063439Phase 2
Key facts
- Status
- Unknown
- Start
- Jan 2010
- Primary completion
- Aug 2014
- Countries
- 1
- Sponsor
- Inje University
- Modality
- Small Molecules
- Drugs
- busulfan
- Conditions
- diffuse large B-cell lymphoma (DLBCL)
01
Overview
Phase 2, open-label trial of busulfan in diffuse large B-cell lymphoma (DLBCL), sponsored by Inje University. Status: unknown.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Patients with high-intermediate/high risk DLBCL at diagnosis or relapsed/refractory DLBCL sensitive to salvage chemotherapy, previously treated with rituximab.
04
Registry description
The purpose of this study is to evaluate the efficacy and toxicity of busulfan, etoposide, cytarabine and melphalan (BuEAM) including intravenous busulfan instead of BCNU of standard BEAM as a conditioning for autologous stem cell transplantation in patients with NHL.
Beyond the preview
Go deeper on NCT01063439.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01063439.